The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management

Lindybeth Sarmiento Varón, Jorge González-Puelma, David Medina-Ortiz, Jacqueline Aldridge, Diego Alvarez-Saravia, Roberto Uribe-Paredes, Marcelo A Navarrete, Lindybeth Sarmiento Varón, Jorge González-Puelma, David Medina-Ortiz, Jacqueline Aldridge, Diego Alvarez-Saravia, Roberto Uribe-Paredes, Marcelo A Navarrete

Abstract

The ongoing COVID-19 pandemic is arguably one of the most challenging health crises in modern times. The development of effective strategies to control the spread of SARS-CoV-2 were major goals for governments and policy makers. Mathematical modeling and machine learning emerged as potent tools to guide and optimize the different control measures. This review briefly summarizes the SARS-CoV-2 pandemic evolution during the first 3 years. It details the main public health challenges focusing on the contribution of mathematical modeling to design and guide government action plans and spread mitigation interventions of SARS-CoV-2. Next describes the application of machine learning methods in a series of study cases, including COVID-19 clinical diagnosis, the analysis of epidemiological variables, and drug discovery by protein engineering techniques. Lastly, it explores the use of machine learning tools for investigating long COVID, by identifying patterns and relationships of symptoms, predicting risk indicators, and enabling early evaluation of COVID-19 sequelae.

Keywords: COVID-19; SARS-CoV-2; long COVID; machine learning; mathematical models; public health policies.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2023 Sarmiento Varón, González-Puelma, Medina-Ortiz, Aldridge, Alvarez-Saravia, Uribe-Paredes and Navarrete.

Figures

Figure 1
Figure 1
Behavior of epidemiological variables during the ongoing pandemic of COVID-19. The figure depicts the timeline of new deaths per million inhabitants (left) and admissions to intensive care unit (ICU) per million inhabitants (right) in relationship with SARS-CoV-2 variants, vaccination thresholds, and non-pharmacological interventions. The stringency index is a composite measure based on nine response indicators including school closures, workplace closures, and travel bans, rescaled to a value from 0 to 100 (100 = strictest). Data acquired from et al. (27), Hasell et al. (28), and Khare et al. (29).
Figure 2
Figure 2
Analysis of long COVID symptoms in patients with positive or negative COVID-19 PCR test. Relative frequency of symptoms in individuals with a positive COVID-19 PCR test (left) as compared to individuals with a negative test. Elaborated on basis of LC symptoms registered by the National COVID Cohort Collaborative (N3C) initiative. Data acquired from (71).
Figure 3
Figure 3
Summary of machine learning applications to fight COVID-19 during the pandemic. General applications of machine learning were classified into 5 categories: i) The design of diagnosis models based on different types of inputs like CT chest, X-ray images, and symptom descriptions. ii) Treatment development. iii) The development of epidemiological models to predict new waves and outbreaks. iv) The simulation of potential scenarios, and monitoring systems to guide public health decisions. v) The diagnosis and identification of risk factors in long COVID.
Figure 4
Figure 4
Developed architecture for COVID-19 diagnosis classification models based on CT chest images and convolutional neural network architectures. Three blocks of layers composed of convolution, batch normalization, max pooling and dropout layers are generated as a pattern extraction strategy, then a flatten layer is used to generate the inputs to the dense layers, which are joined with a layer of batch normalization, followed by three additional full connected layers, which end with a new dropout layer to prevent overfitting, and the final classification layer. ReLU is used as activation functions and the SoftMax function in the classification layer. Finally, the Adam optimizer is used as a loss function binary cross entropy. The developed architecture is an update from previous method for CT chest images classification models developed by our group (34).

References

    1. Shankar S, Mohakuda SS, Kumar A, Nazneen P, Yadav AK, Chatterjee K, et al. . Systematic review of predictive mathematical models of COVID-19 epidemic. Med J Armed Forces India. (2021) 77:S385–392. 10.1016/j.mjafi.2021.05.005
    1. Contreras S, Medina-Ortiz D, Conca C, Olivera-Nappa Á. A novel synthetic model of the glucose-insulin system for patient-wise inference of physiological parameters from small-size OGTT data. Front Bioeng Biotechnol. (2020) 8:195. 10.3389/fbioe.2020.00195
    1. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. (2020) 41:1141–9. 10.1038/s41401-020-0485-4
    1. Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Mutations and evolution of the SARS-CoV-2 spike protein. Viruses. (2022) 14:640. 10.3390/v14030640
    1. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. (2020) 25:278. 10.1111/tmi.13383
    1. Baker MG, Wilson N. The covid-19 elimination debate needs correct data. BMJ. (2020) 371. 10.1136/bmj.m3883
    1. Holmdahl I, Buckee C. Wrong but useful–what covid-19 epidemiologic models can and cannot tell us. N Engl J Med. (2020) 383:303–5. 10.1056/NEJMp2016822
    1. Wu Z, Harrich D, Li Z, Hu D, Li D. The unique features of SARS-CoV-2 transmission: comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus. Rev Med Virol. (2021) 31:e2171. 10.1002/rmv.2171
    1. Li Y, Campbell H, Kulkarni D, Harpur A, Nundy M, Wang X, et al. . The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. Lancet Infect Dis. (2021) 21:193–202. 10.1016/S1473-3099(20)30785-4
    1. Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, Gavenčiak T, et al. . Inferring the effectiveness of government interventions against COVID-19. Science. (2021) 371:eabd9338. 10.1126/science.abd9338
    1. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen HM, et al. . An evidence review of face masks against COVID-19. Proc Natl Acad Sci USA. (2021) 118:e2014564118. 10.1073/pnas.2014564118
    1. Cobey S. Modeling infectious disease dynamics. Science. (2020) 368:713–714. 10.1126/science.abb5659
    1. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. . Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. (2020) 584:257–61. 10.1038/s41586-020-2405-7
    1. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. . Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. (2021) 7:eabd5393. 10.1126/sciadv.abd5393
    1. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. . Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. (2020) 182:812–27. 10.1016/j.cell.2020.06.043
    1. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. (1993) 15:265–302. 10.1093/oxfordjournals.epirev.a036121
    1. To KKW, Hung IFN, Ip JD, Chu AWH, Chan WM, Tam AR, et al. . Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. (2020) 73:e2946–51. 10.1093/cid/ciaa1275
    1. Saad-Roy CM, Morris SE, Metcalf CJE, Mina MJ, Baker RE, Farrar J, et al. . Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science. (2021) 372:363–70. 10.1126/science.abg8663
    1. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. (2021) 398:1407–16. 10.1016/S0140-6736(21)02183-8
    1. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. (2021) 27:2136–43. 10.1038/s41591-021-01583-4
    1. Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, et al. . Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science. (2022) 375:1151–4. 10.1126/science.abl4292
    1. González-Puelma J, Aldridge J, Montes de Oca M, Pinto M, Uribe-Paredes R, Fernández-Goycoolea J, et al. . Mutation in a SARS-CoV-2 haplotype from sub-Antarctic Chile reveals new insights into the SpikeâĂŹs dynamics. Viruses. (2021) 13:883. 10.3390/v13050883
    1. Acevedo ML, Gaete-Argel A, Alonso-Palomares L, de Oca MM, Bustamante A, Gaggero A, et al. . Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. Nat Microbiol. (2022) 7:524–9. 10.1038/s41564-022-01092-1
    1. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. . Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med. (2021) 385:585–94. 10.1056/NEJMoa2108891
    1. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J Interferon Cytokine Res. (2011) 31:41–7. 10.1089/jir.2010.0107
    1. Pulliam JR, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. (2022) 376:eabn4947.
    1. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. . A global database of COVID-19 vaccinations. Nat Hum Behav. (2021) 5:947–53. 10.1038/s41562-021-01122-8
    1. Hasell J. A cross-country database of COVID-19 testing. Sci Data. (2020) 7:345. 10.1038/s41597-020-00688-8
    1. Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. . GISAIDâĂŹs role in pandemic response. China CDC Weekly. (2021) 3:1049. 10.46234/ccdcw2021.255
    1. Calafiore GC, Novara C, Possieri C. A modified SIR model for the COVID-19 contagion in Italy. In: 2020 59th IEEE Conference on Decision and Control (CDC). Jeju: IEEE; (2020). p. 3889–94.
    1. Annas S, Pratama MI, Rifandi M, Sanusi W, Side S. Stability analysis and numerical simulation of SEIR model for pandemic COVID-19 spread in Indonesia. Chaos Solitons Fractals. (2020) 139:110072. 10.1016/j.chaos.2020.110072
    1. Contreras S, Villavicencio HA, Medina-Ortiz D, Biron-Lattes JP, Olivera-Nappa Á. A multi-group SEIRA model for the spread of COVID-19 among heterogeneous populations. Chaos Solitons Fractals. (2020) 136:109925. 10.1016/j.chaos.2020.109925
    1. Contreras S, Biron-Lattes JP, Villavicencio HA, Medina-Ortiz D, Llanovarced-Kawles N, Olivera-Nappa Á. Statistically-based methodology for revealing real contagion trends and correcting delay-induced errors in the assessment of COVID-19 pandemic. Chaos Solitons Fractals. (2020) 139:110087. 10.1016/j.chaos.2020.110087
    1. Sanchez-Daza A, Medina-Ortiz D, Olivera-Nappa A, Contreras S. COVID-19 modeling under uncertainty: statistical data analysis for unveiling true spreading dynamics and guiding correct epidemiological management. In: Modeling, Control and Drug Development for COVID-19 Outbreak Prevention. Springer: (2022). p. 245–82. Available online at:
    1. Bauer S, Contreras S, Dehning J, Linden M, Iftekhar E, Mohr SB, et al. . Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves. PLoS Comput Biol. (2021) 17:e1009288. 10.1371/journal.pcbi.1009288
    1. Contreras S, Dehning J, Mohr SB, Bauer S, Spitzner FP, Priesemann V. Low case numbers enable long-term stable pandemic control without lockdowns. Sci Adv. (2021) 7:eabg2243. 10.1126/sciadv.abg2243
    1. Contreras S, Priesemann V. Risking further COVID-19 waves despite vaccination. Lancet Infect Dis. (2021) 21:745–6. 10.1016/S1473-3099(21)00167-5
    1. Oróstica KY, Contreras S, Mohr SB, Dehning J, Bauer S, Medina-Ortiz D, et al. . Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants. arXiv preprint arXiv:210810018. (2021). 10.48550/arXiv.2108.10018
    1. Contreras S, Oróstica KY, Daza-Sanchez A, Wagner J, Dönges P, Medina-Ortiz D, et al. . Model-based assessment of sampling protocols for infectious disease genomic surveillance. Chaos Solitons Fractals. (2023) 167:113093. 10.1016/j.chaos.2022.113093
    1. Oróstica KY, Contreras S, Sanchez-Daza A, Fernandez J, Priesemann V, Olivera-Nappa Á. New year, new SARS-CoV-2 variant: resolutions on genomic surveillance protocols to face Omicron. Lancet Regional Health Am. (2022) 7:100203. 10.1016/j.lana.2022.100203
    1. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. . COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. (2021) 397:1725–735. 10.1016/S0140-6736(21)00790-X
    1. Joshi G, Borah P, Thakur S, Sharma P, Mayank, Poduri R. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go? Hum Vaccines Immunotherapeut. (2021) 17:4714–40. 10.1080/21645515.2021.1995283
    1. Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Diff. (2021) 28:626–39. 10.1038/s41418-020-00720-9
    1. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. (2021) 21:73–82. 10.1038/s41577-020-00480-0
    1. Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. (2021) 892:173751. 10.1016/j.ejphar.2020.173751
    1. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. (2021) 6:28. 10.1038/s41541-021-00292-w
    1. Baden L, El Sahly H, Essink B, et al. . Učinkovitost in varnost cepiva mRNA-1273 SARS-CoV-2. N Engl J Med. (2021) 384:403–416. 10.1056/NEJMoa2035389
    1. Sa M, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BionTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. (2021) 25:1663–9. 10.26355/eurrev_202102_24877
    1. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. . Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. (2021) 326:1390–9. 10.1001/jama.2021.15072
    1. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine–United States, December 14-23, 2020. Am J Transpl. (2021) 21:1332. 10.1111/ajt.16516
    1. Friedensohn L, Levin D, Fadlon-Derai M, Gershovitz L, Fink N, Glassberg E, et al. . Myocarditis following a third BNT162b2 vaccination dose in military recruits in Israel. JAMA. (2022) 327:1611–2. 10.1001/jama.2022.4425
    1. See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. . US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021. JAMA. (2021) 325:2448–56. 10.1001/jama.2021.7517
    1. Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. . Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Network Open. (2022) 5:e228879-e228879. 10.1001/jamanetworkopen.2022.8879
    1. Grome HN, Threlkeld M, Threlkeld S, Newman C, Martines RB, Reagan-Steiner S, et al. . Fatal multisystem inflammatory syndrome in adult after SARS-CoV-2 natural infection and COVID-19 vaccination. Emerg Infect Dis. (2021) 27:2914. 10.3201/eid2711.211612
    1. Miao G, Chen Z, Cao H, Wu W, Chu X, Liu H, et al. . From immunogen to COVID-19 vaccines: prospects for the post-pandemic era. Biomed Pharmacother. (2023) 2023:114208. 10.1016/j.biopha.2022.114208
    1. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. . Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. (2022) 54:1473–87. 10.1080/07853890.2022.2076901
    1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Group WCCDW, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2021) 22:e102–7. 10.1016/S1473-3099(21)00703-9
    1. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med. (2021) 27:626–31. 10.1038/s41591-021-01292-y
    1. Boix V, Merino E. Post-COVID syndrome. The never ending challenge. Med Clin. (2022) 158:178. 10.1016/j.medcle.2021.10.005
    1. Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. (2022) 32:e2315. 10.1002/rmv.2315
    1. Fernández-de Las-Pe nas C, Notarte KI, Peligro PJ, Velasco JV, Ocampo MJ, Henry BM, et al. . Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. (2022) 14:2629. 10.3390/v14122629
    1. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. (2021) 76:405–7. 10.1136/thoraxjnl-2020-216377
    1. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. (2022) 185:881–95. 10.1016/j.cell.2022.01.014
    1. Carfì A, Bernabei R, Landi F. Against COVID-19. Post-Acute Care Study Group: for the Gemelli Against CCOVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 9:603. 10.1001/jama.2020.12603
    1. Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. . Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. (2021) 11:e048391. 10.1136/bmjopen-2020-048391
    1. Tanne JH. Covid-19: even mild infections can cause long term heart problems, large study finds. Br Med J. (2022) 2022:378. 10.1136/bmj.o378
    1. Qin W, Chen S, Zhang Y, Dong F, Zhang Z, Hu B, et al. . Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. Eur Respir J. (2021) 58:2003677. 10.1183/13993003.03677-2020
    1. Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. . Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. (2021) 10:386. 10.3390/cells10020386
    1. Lamers MM, Beumer J, Van Der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. . SARS-CoV-2 productively infects human gut enterocytes. Science. (2020) 369:50–4. 10.1126/science.abc1669
    1. Bhattacharyya A, Seth A, Rai S. The effects of long COVID-19, its severity, and the need for immediate attention: analysis of clinical trials and Twitter data. medRxiv. (2022) 2022–09. 10.1101/2022.09.13.22279833
    1. Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. . The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. (2021) 28:427–43. 10.1093/jamia/ocaa196
    1. Alyasseri ZAA, Al-Betar MA, Doush IA, Awadallah MA, Abasi AK, Makhadmeh SN, et al. . Review on COVID-19 diagnosis models based on machine learning and deep learning approaches. Expert Syst. (2022) 39:e12759. 10.1111/exsy.12759
    1. de Fátima Cobre A, Surek M, Stremel DP, Fachi MM, Borba HHL, Tonin FS, et al. . Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning. Comput Biol Med. (2022) 146:105659. 10.1016/j.compbiomed.2022.105659
    1. Kolozsvári LR, Bérczes T, Hajdu A, Gesztelyi R, Tiba A, Varga I, et al. . Predicting the epidemic curve of the coronavirus (SARS-CoV-2) disease (COVID-19) using artificial intelligence: an application on the first and second waves. Inform Med Unlocked. (2021) 25:100691. 10.1016/j.imu.2021.100691
    1. Chandra R, Jain A, Singh Chauhan D. Deep learning via LSTM models for COVID-19 infection forecasting in India. PLoS ONE. (2022) 17:e0262708. 10.1371/journal.pone.0262708
    1. Lalmuanawma S, Hussain J, Chhakchhuak L. Applications of machine learning and artificial intelligence for Covid-19 (SARS-CoV-2) pandemic: a review. Chaos Solitons Fractals. (2020) 139:110059. 10.1016/j.chaos.2020.110059
    1. Zoabi Y, Deri-Rozov S, Shomron N. Machine learning-based prediction of COVID-19 diagnosis based on symptoms. npj Digit Med. (2021) 4:1–5. 10.1038/s41746-020-00372-6
    1. Zhao L, Lediju Bell MA. A review of deep learning applications in lung ultrasound imaging of COVID-19 patients. BME Front. (2022) 2022:9780173. 10.34133/2022/9780173
    1. Dang T, Han J, Xia T, Spathis D, Bondareva E, Siegele-Brown C, et al. . Exploring longitudinal cough, breath, and voice data for COVID-19 progression prediction via sequential deep learning: model development and validation. J Med Internet Res. (2022) 24:e37004. 10.2196/37004
    1. Jin W, Dong S, Dong C, Ye X. Hybrid ensemble model for differential diagnosis between COVID-19 and common viral pneumonia by chest X-ray radiograph. Comput Biol Med. (2021) 131:104252. 10.1016/j.compbiomed.2021.104252
    1. Soares E, Angelov P, Biaso S, Froes MH, Abe DK. SARS-CoV-2 CT-scan dataset: a large dataset of real patients CT scans for SARS-CoV-2 identification. MedRxiv. (2020). 10.1101/2020.04.24.20078584
    1. Abadi M, Barham P, Chen J, Chen Z, Davis A, Dean J, et al. . TensorFlow: a system for Large-Scale machine learning. In: 12th USENIX Symposium on Operating Systems Design Implementation (OSDI 16). (2016). p. 265–83. Available online at:
    1. Alafif T, Tehame AM, Bajaba S, Barnawi A, Zia S. Machine and deep learning towards COVID-19 diagnosis and treatment: survey, challenges, and future directions. Int J Environ Res Public Health. (2021) 18:1117. 10.3390/ijerph18031117
    1. Lv H, Shi L, Berkenpas JW, Dao FY, Zulfiqar H, Ding H, et al. . Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Brief Bioinform. (2021) 22:bbab320. 10.1093/bib/bbab320
    1. Law JN, Akers K, Tasnina N, Della Santina CM, Kshirsagar M, Klein-Seetharaman J, et al. . Identifying human interactors of SARS-CoV-2 proteins and drug targets for COVID-19 using network-based label propagation. arXiv preprint arXiv:200601968. (2020).
    1. Ray S, Lall S, Bandyopadhyay S. A deep integrated framework for predicting SARS-CoV2-human protein-protein interaction. IEEE Trans Emerg Top Comput Intell. (2022) 6:1463–72. 10.1109/TETCI.2022.3182354
    1. Du BX, Qin Y, Jiang YF, Xu Y, Yiu SM, Yu H, et al. . Compound-protein interaction prediction by deep learning: databases, descriptors and models. Drug Discov Today. (2022) 27:1350–66. 10.1016/j.drudis.2022.02.023
    1. Mylonas SK, Axenopoulos A, Daras P. DeepSurf: a surface-based deep learning approach for the prediction of ligand binding sites on proteins. Bioinformatics. (2021) 37:1681–90. 10.1093/bioinformatics/btab009
    1. Liu Q, Wang PS, Zhu C, Gaines BB, Zhu T, Bi J, et al. . OctSurf: efficient hierarchical voxel-based molecular surface representation for protein-ligand affinity prediction. J Mol Graphics Model. (2021) 105:107865. 10.1016/j.jmgm.2021.107865
    1. Jones D, Kim H, Zhang X, Zemla A, Stevenson G, Bennett WD, et al. . Improved protein-ligand binding affinity prediction with structure-based deep fusion inference. J Chem Inf Model. (2021) 61:1583–92. 10.1021/acs.jcim.0c01306
    1. Feng Z, Chen M, Liang T, Shen M, Chen H, Xie XQ. Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research. Brief Bioinform. (2021) 22:882–95. 10.1093/bib/bbaa155
    1. Zhavoronkov A, Aladinskiy V, Zhebrak A, Zagribelnyy B, Terentiev V, Bezrukov D, et al. . Potential COVID-2019 3C-like protease inhibitors designed using generative deep learning approaches. ChemRxiv. Preprint. (2020) 11:102. 10.26434/chemrxiv.11829102
    1. Tang B, He F, Liu D, He F, Wu T, Fang M, et al. . AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2. Biomolecules. (2022) 12:746. 10.3390/biom12060746
    1. Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol Inform. (2020) 39:2000028. 10.1002/minf.202000028
    1. Srinivasan S, Batra R, Chan H, Kamath G, Cherukara MJ, Sankaranarayanan SK. Artificial intelligence-guided De novo molecular design targeting COVID-19. ACS Omega. (2021) 6:12557–66. 10.1021/acsomega.1c00477
    1. Wang Z, Liu M, Luo Y, Xu Z, Xie Y, Wang L, et al. . Advanced graph and sequence neural networks for molecular property prediction and drug discovery. Bioinformatics. (2022) 38:2579–86. 10.1093/bioinformatics/btac112
    1. Medina-Ortiz D, Contreras S, Amado-Hinojosa J, Torres-Almonacid J, Asenjo JA, Navarrete M, et al. . Generalized property-based encoders and digital signal processing facilitate predictive tasks in protein engineering. Front Mol Biosci. (2022) 9:898627. 10.3389/fmolb.2022.898627
    1. Ferruz N, Höcker B. Controllable protein design with language models. Nat Mach Intell. (2022) 4:521–32. 10.1038/s42256-022-00499-z
    1. Wigh DS, Goodman JM, Lapkin AA. A review of molecular representation in the age of machine learning. Wiley Interdisc Rev Comput Mol Sci. (2022) 12:e1603. 10.1002/wcms.1603
    1. Verkuil R, Kabeli O, Du Y, Wicky BI, Milles LF, Dauparas J, et al. . Language models generalize beyond natural proteins. bioRxiv. (2022) 10.1101/2022.12.21.521521
    1. Minh D, Wang HX, Li YF, Nguyen TN. Explainable artificial intelligence: a comprehensive review. Artif Intell Rev. (2022) 55:3503–68. 10.1007/s10462-021-10088-y
    1. Chen CC, Chang CK, Chiu CC, Yang TY, Hao WR, Lin CH, et al. . Machine learning analyses revealed distinct arterial pulse variability according to side effects of Pfizer-BioNTech COVID-19 vaccine (BNT162b2). J Clin Med. (2022) 11:6119. 10.3390/jcm11206119
    1. Abbaspour S, Robbins GK, Blumenthal KG, Hashimoto D, Hopcia K, Mukerji SS, et al. . Identifying modifiable predictors of COVID-19 vaccine side effects: a machine learning approach. Vaccines. (2022) 10:1747. 10.3390/vaccines10101747
    1. Flora J, Khan W, Jin J, Jin D, Hussain A, Dajani K, et al. . Usefulness of vaccine adverse event reporting system for machine-learning based vaccine research: A Case study for COVID-19 vaccines. Int J Mol Sci. (2022) 23:8235. 10.3390/ijms23158235
    1. Gupta M, Jain R, Taneja S, Chaudhary G, Khari M, Verdú E. Real-time measurement of the uncertain epidemiological appearances of COVID-19 infections. Appl Soft Comput. (2021) 101:107039. 10.1016/j.asoc.2020.107039
    1. Mansour RF, Escorcia-Gutierrez J, Gamarra M, Gupta D, Castillo O, Kumar S. Unsupervised deep learning based variational autoencoder model for COVID-19 diagnosis and classification. Pattern Recogn Lett. (2021) 151:267–74. 10.1016/j.patrec.2021.08.018
    1. Wang D, Zuo F, Gao J, He Y, Bian Z, Bernardes SD, et al. . Agent-based simulation model and deep learning techniques to evaluate and predict transportation trends around COVID-19. arXiv preprint arXiv:201009648. (2020). 10.48550/arXiv.2010.09648
    1. Kompella V, Capobianco R, Jong S, Browne J, Fox S, Meyers L, et al. . Reinforcement learning for optimization of COVID-19 mitigation policies. arXiv preprint arXiv:201010560. (2020). 10.48550/arXiv.2010.10560
    1. Medina-Ortiz D, Contreras S, Barrera-Saavedra Y, Cabas-Mora G, Olivera-Nappa Á. Country-wise forecast model for the effective reproduction number R t of coronavirus disease. Front Phys. (2020) 8:304. 10.3389/fphy.2020.00304
    1. Contreras S, Villavicencio HA, Medina-Ortiz D, Saavedra CP, Olivera-Nappa Á. Real-time estimation of R t for supporting public-health policies against COVID-19. Front Public Health. (2020). 8:556689. 10.3389/fpubh.2020.556689
    1. Polyzos S, Samitas A, Spyridou AE. Tourism demand and the COVID-19 pandemic: an LSTM approach. Tour Recreat Res. (2021) 46:175–87. 10.1080/02508281.2020.1777053
    1. Hills S, Eraso Y. Factors associated with non-adherence to social distancing rules during the COVID-19 pandemic: a logistic regression analysis. BMC Public Health. (2021) 21:1–25. 10.1186/s12889-021-10379-7
    1. Saba AI, Elsheikh AH. Forecasting the prevalence of COVID-19 outbreak in Egypt using nonlinear autoregressive artificial neural networks. Process Safety Environ Protect. (2020) 141:1–8. 10.1016/j.psep.2020.05.029
    1. Singh RK, Rani M, Bhagavathula AS, Sah R, Rodriguez-Morales AJ, Kalita H, et al. . Prediction of the COVID-19 pandemic for the top 15 affected countries: Advanced autoregressive integrated moving average (ARIMA) model. JMIR Public Health Surveill. (2020) 6:e19115. 10.2196/19115
    1. Ketu S, Mishra PK. Enhanced Gaussian process regression-based forecasting model for COVID-19 outbreak and significance of IoT for its detection. Appl Intell. (2021) 51:1492–512. 10.1007/s10489-020-01889-9
    1. Castillo Ossa LF, Chamoso P, Arango-López J, Pinto-Santos F, Isaza GA, Santa-Cruz-González C, et al. . A hybrid model for COVID-19 monitoring and prediction. Electronics. (2021) 10:799. 10.3390/electronics10070799
    1. Cheng FY, Joshi H, Tandon P, Freeman R, Reich DL, Mazumdar M, et al. . Using machine learning to predict ICU transfer in hospitalized COVID-19 patients. J Clin Med. (2020) 9:1668. 10.3390/jcm9061668
    1. Alamrouni A, Aslanova F, Mati S, Maccido HS, Jibril AA, Usman A, et al. . Multi-regional modeling of cumulative COVID-19 cases integrated with environmental forest knowledge estimation: a deep learning ensemble approach. Int J Environ Res Public Health. (2022) 19:738. 10.3390/ijerph19020738
    1. Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. . Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. (2022) 4:e532–41. 10.1016/S2589-7500(22)00048-6
    1. Binka M, Klaver B, Cua G, Wong AW, Fibke C, Velásquez García HA, et al. . An elastic net regression model for identifying long COVID patients using health administrative data: a population-based study. In: Open Forum Infectious Diseases. vol. 9. Oxford: Oxford University Press US; (2022). p. ofac640.
    1. Fritsche LG, Jin W, Admon AJ, Mukherjee B. Characterizing and predicting post-acute sequelae of SARS CoV-2 infection (PASC) in a large academic medical center in the US. medRxiv. (2022) 10.1101/2022.10.21.22281356
    1. Sengupta S, Loomba J, Sharma S, Brown DE, Thorpe L, Haendel MA, et al. . Analyzing historical diagnosis code data from NIH N3C and RECOVER Programs using deep learning to determine risk factors for Long COVID. arXiv preprint arXiv:221002490. (2022) 10.1109/BIBM55620.2022.9994851
    1. Gupta A, Jain V, Singh A. Stacking ensemble-based intelligent machine learning model for predicting post-COVID-19 complications. N Generat Comput. (2022) 40:987–1007. 10.1007/s00354-021-00144-0

Source: PubMed

3
订阅